Phase II study of CI-958 in patients with hormone refractory prostate carcinoma.
Invest New Drugs
; 22(2): 181-4, 2004 Apr.
Article
en En
| MEDLINE
| ID: mdl-14739667
ABSTRACT
A phase II trial of CI-958 (NSC #635371), a new benzothiopyranoindazole was performed in patients with hormone refractory prostate carcinoma using prostate specific antigen (PSA) levels for response assessment. Twenty-two patients were entered on this study and twenty one were eligible. Toxicity consisted mainly of granulocytopenia (71% grade 3 or 4), but there were no significant infections. Two patients were removed from study due to asymptomatic decreases in cardiac ejection fraction. Of 21 evaluable patients, there were four responders (19%, CI 0-35%).
Search on Google
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Próstata
/
Adenocarcinoma
/
Drogas en Investigación
/
Indazoles
Tipo de estudio:
Clinical_trials
Límite:
Adult
/
Aged
/
Aged80
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2004
Tipo del documento:
Article